Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating on May 9.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
David Risinger has given his Buy rating due to a combination of factors including the promising results from the SURMOUNT-5 trial. Eli Lilly’s Zepbound demonstrated superior weight loss outcomes compared to Novo Nordisk’s Wegovy, with a 20.2% reduction in weight over 72 weeks, significantly outperforming Wegovy’s 13.7%. This superior efficacy, coupled with comparable tolerability between the two treatments, underscores a favorable benefit-risk profile for Zepbound.
Additionally, Eli Lilly is advancing its research with the ongoing ATTAIN-MAINTAIN trial, which explores the transition from injectable treatments to its oral GLP-1, orforglipron. This trial aims to maintain the weight loss achieved in SURMOUNT-5, potentially broadening the therapeutic options for patients. These strategic advancements and clinical successes contribute to the positive outlook for Eli Lilly’s stock, supporting Risinger’s Buy recommendation.
Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, AnaptysBio, and Sanofi. According to TipRanks, Risinger has an average return of 7.4% and a 50.52% success rate on recommended stocks.
In another report released on May 9, Bank of America Securities also maintained a Buy rating on the stock with a $1,000.00 price target.